Post hoc analysis data
| Mean change (95% CI) in score from baseline to Month 12 | ||||
|---|---|---|---|---|
| DAS28 status at Month 4 | N | Synovitis (wrist) | Osteitis (wrist and hand) | Erosion (wrist and hand) |
| Remission (<2.6)* | 4 | −3.00 (−6.90 to 0.90) | −2.75 (−8.47 to 2.97) | −4.75 (−13.11 to 3.61) |
| LDAS (≤3.2) | 11 | −2.64 (−4.15 to −1.13) | −4.09 (−8.44 to 0.26) | −2.18 (−5.12 to 0.85) |
| MDAS (>3.2–5.1) | 9 | −1.00 (−2.84 to 0.84) | −3.22 (−8.17 to 1.73) | 1.56 (0.27 to 2.84) |
| HDAS (>5.1) | 3 | 0.00 (0.00 to 0.00) | −1.33 (−5.13 to 2.46) | 1.33 (−1.54 to 4.20) |
Data are as observed for patients treated in the open-label extension who were originally randomised to abatacept+MTX, who had data available at the visits of interest.
*Subset of LDAS.
DAS28, Disease Activity Score 28; HDAS, high disease activity state; LDAS, low disease activity state; MDAS, moderate disease activity state; MTX, methotrexate.